Skip to main content

Advertisement

SpringerLink
Log in

New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders

  • Geropsychiatry & Cognitive Disorders of Late Life (P Newhouse, Section Editor)
  • Published:
Current Behavioral Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This paper aims to review novel trends in cholinergic neuroimaging in Alzheimer and Lewy body parkinsonian disorders.

Recent Findings

The spectrum of cholinergic imaging is expanding with the availability of spatially more precise radioligands that allow assessment of previously less recognized subcortical and cortical structures with more dense cholinergic innervation. In addition, advances in MRI techniques now allow quantitative structural or functional assessment of both the cholinergic forebrain and the pedunculopontine nucleus, which may serve as non-invasive prognostic predictors. Multimodal imaging approaches, such as PET-MRI or multiligand PET, offer new insights into the dynamic and interactive roles of the cholinergic system at both local and larger-scale neural network levels.

Summary

Our understanding of the heterogeneous roles of the cholinergic system in age-related diseases is evolving. Multimodal imaging approaches that provide complimentary views of the cholinergic system will be necessary to shed light on the impact of cholinergic degeneration on regional and large-scale neural networks that underpin clinical symptom manifestation in neurodegeneration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

AD:

Alzheimer disease

cBF:

Cholinergic basal forebrain

DTI:

Diffusion tensor imaging

PD:

Parkinson disease

LBD:

Lewy body dementias

Ch4:

Nucleus basalis of Meynert

PPN:

Pedunculopontine nucleus

VAChT:

Vesicular Acetylcholine Transporter

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bohnen NI, Grothe MJ, Ray NJ, Müller MLTM, Teipel SJ. Recent advances in cholinergic imaging and cognitive decline—revisiting the cholinergic hypothesis of dementia. Curr Geriatr Rep. 2018;7:1–11.

    PubMed  PubMed Central  Google Scholar 

  2. Bohnen NI, Kanel P, Müller MLTM (2018) Molecular imaging of the cholinergic system in Parkinson’s disease. In: Politis M, editor. International Review of Neurobiology [Internet]. Academic Press; [cited 2020 Mar 25]. p. 211–50. Available from: http://www.sciencedirect.com/science/article/pii/S0074774218300564

  3. Kotagal V, Müller MLTM, Kaufer DI, Koeppe RA, Bohnen NI. Thalamic cholinergic innervation is spared in Alzheimer disease compared to Parkinsonian disorders. Neurosci Lett. 2012;514:169–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Mazère J, Lamare F, Allard M, Fernandez P, Mayo W. 123I-Iodobenzovesamicol SPECT imaging of cholinergic systems in dementia with Lewy bodies. J Nucl Med. 2017;58:123–8.

    PubMed  Google Scholar 

  5. Nejad-Davarani S, Koeppe RA, Albin RL, Frey KA, Müller MLTM, Bohnen NI. Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2019;24:322–7.

    PubMed  Google Scholar 

  6. •• Ray NJ, Bradburn S, Murgatroyd C, Toseeb U, Mir P, Kountouriotis GK, et al. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s disease. Brain. 2018;141:165–76 First study to demonstrate that baseline Ch4 volumes in de novo PD could predict risk of MCI over 5 years. In agreement with the AD literature, deterioration in the posterior Ch4 (Ch4p) may be characteristic of MCI in PD, as only volumes in this region could differentiate PD with suspected MCI from controls at baseline.

    PubMed  Google Scholar 

  7. Mesulam MM. The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer’s disease. Prog Brain Res. 1996;109:285–97.

    CAS  PubMed  Google Scholar 

  8. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983;214:170–97.

    CAS  PubMed  Google Scholar 

  9. Mesulam M-M, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1–Ch6). Neuroscience. 1983;10:1185–201.

    CAS  PubMed  Google Scholar 

  10. Heckers S, Geula C, Mesulam MM. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol. 1992;325:68–82.

    CAS  PubMed  Google Scholar 

  11. Zhang C, Zhou P, Yuan T. The cholinergic system in the cerebellum: from structure to function. Rev Neurosci. 2016;27:769–76.

    PubMed  Google Scholar 

  12. Fibiger HC. The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res. 1982;257:327–88.

    CAS  PubMed  Google Scholar 

  13. Mesulam MM, Mash D, Hersh L, Bothwell M, Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J Comp Neurol. 1992;323:252–68.

    CAS  PubMed  Google Scholar 

  14. Dautan D, Huerta-Ocampo I, Witten IB, Deisseroth K, Bolam JP, Gerdjikov T, et al. A major external source of cholinergic innervation of the striatum and nucleus accumbens originates in the brainstem. J Neurosci. 2014;34:4509–18.

    PubMed  PubMed Central  Google Scholar 

  15. Dautan D, Hacioğlu Bay H, Bolam JP, Gerdjikov TV, Mena-Segovia J (2016) Extrinsic sources of cholinergic innervation of the striatal complex: a whole-brain mapping analysis. Front Neuroanat [Internet]. [cited 2020 Jun 10];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722731/

  16. Irie T, Fukushi K, Namba H, Iyo M, Tamagami H, Nagatsuka S, et al. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer’s disease. J Nucl Med. 1996;37:649–55.

    CAS  PubMed  Google Scholar 

  17. Shute CC, Lewis PR. Electron microscopy of cholinergic terminals and acetylcholinesterase-containing neurones in the hippocampal formation of the rat. Z Zellforsch Mikrosk Anat. 1966;69:334–43.

    CAS  PubMed  Google Scholar 

  18. Petrou M, Koeppe R, Scott P, Bohnen N, Kilbourn M, Frey K (2012) PET imaging of the vesicular acetylcholine transporter. J Nucl Med. Society of Nuclear Medicine; 53:290–290.

  19. Liu AKL, Chang RC-C, Pearce RKB, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol. 2015;129:527–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Pepeu G, Grazia GM. The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Res. 2017;1670:173–84.

    CAS  PubMed  Google Scholar 

  21. Teipel SJ, Flatz WH, Heinsen H, Bokde ALW, Schoenberg SO, Stöckel S, et al. Measurement of basal forebrain atrophy in Alzheimer’s disease using MRI. Brain Oxford Academic. 2005;128:2626–44.

    Google Scholar 

  22. Kilimann I, Grothe M, Heinsen H, Alho EJL, Grinberg L, Amaro E, et al. Subregional basal forebrain atrophy in Alzheimer’s disease: a multicenter study. J Alzheimers Dis. 2014;40:687–700.

    PubMed  PubMed Central  Google Scholar 

  23. Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage. 2008;42:1127–41.

    PubMed  Google Scholar 

  24. Kilimann I, Hausner L, Fellgiebel A, Filippi M, Würdemann TJ, Heinsen H, et al. Parallel atrophy of cortex and basal forebrain cholinergic system in mild cognitive impairment. Cereb Cortex Oxford Academic. 2017;27:1841–8.

    Google Scholar 

  25. Zrinzo L, Zrinzo LV, Tisch S, Limousin PD, Yousry TA, Afshar F, et al. Stereotactic localization of the human pedunculopontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization. Brain. 2008;131:1588–98.

    PubMed  Google Scholar 

  26. Gargouri F, Gallea C, Mongin M, Pyatigorskaya N, Valabregue R, Ewenczyk C, et al. Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson’s disease. Mov Disord. 2019;34:516–25.

    PubMed  Google Scholar 

  27. •• Albin RL, Bohnen NI, Muller MLTM, Dauer WT, Sarter M, Frey KA, et al. Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study. J Comp Neurol. 2018;526:2884–97 First anatomic study identifying previously unrecognized small structures with prominent cholinergic innervation, such as the lateral geniculate nucleus and the flocculonodular lobules.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Colloby SJ, McKeith IG, Wyper DJ, O’Brien JT, Taylor J-P. Regional covariance of muscarinic acetylcholine receptors in Alzheimer’s disease using (R, R) [(123)I]-QNB SPECT. J Neurol. 2015;262:2144–53.

    CAS  PubMed  Google Scholar 

  29. Colloby SJ, Field RH, Wyper DJ, O’Brien JT, Taylor J-P. A spatial covariance 123I-5IA-85380 SPECT study of α4β2 nicotinic receptors in Alzheimer’s disease. Neurobiol Aging. 2016;47:83–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Colloby SJ, McKeith IG, Burn DJ, Wyper DJ, O’Brien JT, Taylor J-P. Cholinergic and perfusion brain networks in Parkinson disease dementia. Neurology. 2016;87:178–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Kanel P, Müller MLTM, van der Zee S, Sanchez-Catasus CA, Koeppe RA, Frey KA, et al. (2020) Topography of cholinergic changes in dementia with Lewy bodies and key neural network hubs. JNP. American Psychiatric Publishing; appi.neuropsych.19070165.

  32. Bedard M-A, Aghourian M, Legault-Denis C, Postuma RB, Soucy J-P, Gagnon J-F, et al. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with 18F-FEOBV. Sleep Med. 2019;58:35–41.

    PubMed  Google Scholar 

  33. •• Schmitz TW, Spreng RN, Weiner MW, Aisen P, Petersen R, Jack CR, et al. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology. Nature Communications. 2016;7:13249 First paper to demonstrate that Ch4 (Ch4) degeneration precedes and predicts EC degeneration, which in turn predicts memory impairment in AD pathology. The authors provide compelling evidence for an updated model of AD pathophysiology.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. •• Fernández-Cabello S, Kronbichler M, KRA VD, Goodman JA, Spreng RN, Schmitz TW. Basal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration. Brain. 2020;143:993–1009 Building on their previous research [33], the authors present further evidence in two independent samples (N > 800 combined) that Ch4 atrophy predicts EC atrophy, which in turn predicts neocortical atrophy over 2 years. Additionally, they report that CSF pTau/amyloid-β ratios moderated this predictive relationship.

    PubMed  PubMed Central  Google Scholar 

  35. Cantero JL, Atienza M, Lage C, Zaborszky L, Vilaplana E, Lopez-Garcia S, et al. Atrophy of basal forebrain initiates with tau pathology in individuals at risk for Alzheimer’s disease. Cereb Cortex. Oxford Academic. 2020;30:2083–98.

    Google Scholar 

  36. Schmitz TW, Mur M, Aghourian M, Bedard M-A, Spreng RN. Longitudinal Alzheimer’s degeneration reflects the spatial topography of cholinergic basal forebrain projections. Cell Rep. 2018;24:38–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Barrett MJ, Sperling SA, Blair JC, Freeman CS, Flanigan JL, Smolkin ME, et al. Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease. J Neurol Neurosurg Psychiatry. BMJ Publishing Group Ltd; 2019;90:1251–1256.

  38. Schulz J, Pagano G, Fernández Bonfante JA, Wilson H, Politis M. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease. Brain. 2018;141:1501–16.

    PubMed  PubMed Central  Google Scholar 

  39. •• Pereira JB, Hall S, Jalakas M, Grothe MJ, Strandberg O, Stomrud E, et al. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease. Neurobiol Dis. 2020;139:104831 First longitudinal study examining GM cBF volumes over a 10-year period in patients with PD, PDD and controls. At baseline, PDD and those who would convert to PDD later showed significant Ch4 atrophy compared to controls. Both PDD groups showed Ch1/2 atrophy over time compared with controls and PD-stable. Longitudinal changes in Ch4 volumes significantly predicted conversion to PDD over 10 years.

    CAS  PubMed  Google Scholar 

  40. • Jethwa KD, Dhillon P, Meng D, Auer DP. Alzheimer’s disease neuroimaging initiative. Are linear measurements of the nucleus basalis of Meynert suitable as a diagnostic biomarker in mild cognitive impairment and alzheimer disease? AJNR Am J Neuroradiol. 2019;40:2039–44 This paper provides initial evidence that a simple linear measurement of Ch4 thickness could show clinical promise to differentiate controls from those with AD and late MCI. The paper below [41] further developed on this technique by using susceptibility weighted phase sensitive inversion recovery (SW-PSIR) to improve Ch4 contrast resolution and interrater reliability of Ch4 thickness.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Jethwa KD, Aphiwatthanasumet K, Mougin O, Bowtell R, Auer D, Gowland P. Phase enhanced PSIR T1 weighted imaging improves contrast resolution of the nucleus basalis of Meynert at 7 T: a preliminary study. Magn Reson Imaging. 2019;61:296–9.

    PubMed  Google Scholar 

  42. • Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, et al. Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease. Scientific Reports. Nature Publishing Group; 2017;7:11706. First study to assess the effect of cholinergic medication on cBF integrity in AD. The acetylcholinesterase inhibitor (AChEI), Donepezil, significantly reduced annual cBF GM atrophy in patients with prodromal AD, with the largest treatment effects witnessed in Ch4 (Ch4) and Ch1/2.

  43. Nemy M, Cedres N, Grothe MJ, Muehlboeck J-S, Lindberg O, Nedelska Z, et al. Cholinergic white matter pathways make a stronger contribution to attention and memory in normal aging than cerebrovascular health and nucleus basalis of Meynert. Neuroimage. 2020;211:116607.

    PubMed  Google Scholar 

  44. Liu Q, Zhu Z, Teipel SJ, Yang J, Xing Y, Tang Y, et al. White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment. No Dementia Front Aging Neurosci. 2017;9:47.

    PubMed  Google Scholar 

  45. Lanskey JH, McColgan P, Schrag AE, Acosta-Cabronero J, Rees G, Morris HR, et al. Can neuroimaging predict dementia in Parkinson’s disease? Brain. 2018;141:2545–60.

    PubMed  PubMed Central  Google Scholar 

  46. Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190–9.

    PubMed  Google Scholar 

  47. Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77:585–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Bohnen NI, Müller MLTM, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73:1670–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. • Bohnen NI, Frey KA, Studenski S, Kotagal V, Koeppe RA, Scott PJH, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81:1611–6 Our recent paper shows for the first time distinct subcortical cholinergic system changes between PD fallers vs. freezers.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Bohnen NI, Kanel P, Zhou Z, Koeppe RA, Frey KA, Dauer WT, et al. Cholinergic system changes of falls and freezing of gait in Parkinson’s disease. Ann Neurol. 2019;85:538–49.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Schweder PM, Hansen PC, Green AL, Quaghebeur G, Stein J, Aziz TZ. Connectivity of the pedunculopontine nucleus in parkinsonian freezing of gait. Neuroreport. 2010;21:914–6.

    PubMed  Google Scholar 

  52. Fling BW, Cohen RG, Mancini M, Nutt JG, Fair DA, Horak FB. Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. Brain. 2013;136:2405–18.

    PubMed  PubMed Central  Google Scholar 

  53. Alho ATDL, Hamani C, Alho EJL, da Silva RE, Santos GAB, Neves RC, et al. Magnetic resonance diffusion tensor imaging for the pedunculopontine nucleus: proof of concept and histological correlation. Brain Struct Funct. 2017;222:2547–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. • Craig CE, Jenkinson NJ, Brittain J-S, Grothe MJ, Rochester L, Silverdale M, et al. (2020) Pedunculopontine nucleus microstructure predicts postural and gait symptoms in Parkinson’s disease. Mov Disord. Our recent paper demonstrated how a novel MRI measure of PPN microstructural integrity may provide a non-invasive biomarker of PIGD from early PD. Results showed that axial diffusivity (aD) in the PPN, but not Ch4, predicted future PIGD symptoms in PD.

  55. Bartels AL, Leenders KL. Brain imaging in patients with freezing of gait. Mov Disord. 2008;23:S461–7.

    PubMed  Google Scholar 

  56. Snijders AH, Leunissen I, Bakker M, Overeem S, Helmich RC, Bloem BR, et al. Gait-related cerebral alterations in patients with Parkinson’s disease with freezing of gait. Brain. 2011;134:59–72.

    PubMed  Google Scholar 

  57. Peterson DS, Pickett KA, Duncan R, Perlmutter J, Earhart GM (2014) Gait-related brain activity in people with Parkinson disease with freezing of gait. PLoS One [Internet]. [cited 2020 Jun 10];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940915/

  58. Vossel S, Geng JJ, Fink GR. Dorsal and ventral attention systems: distinct neural circuits but collaborative roles. Neuroscientist. 2014;20:150–9.

    PubMed  PubMed Central  Google Scholar 

  59. Ebersbach G, Trottenberg T, Hättig H, Schelosky L, Schrag A, Poewe W. Directional bias of initial visual exploration: a symptom of neglect in Parkinson’s disease. Brain. Oxford Academic. 1996;119:79–87.

    PubMed  Google Scholar 

  60. Dieterich M, Bense S, Lutz S, Drzezga A, Stephan T, Bartenstein P, et al. Dominance for vestibular cortical function in the non-dominant hemisphere. Cerebral Cortex. United Kingdom: Oxford University Press; 2003;13:994–1007.

  61. Grothe MJ, Heinsen H, Amaro E, Grinberg LT, Teipel SJ. Cognitive correlates of basal forebrain atrophy and associated cortical hypometabolism in mild cognitive impairment. Cereb Cortex. 2016;26:2411–26.

    PubMed  Google Scholar 

  62. Ballinger EC, Ananth M, Talmage DA, Role LW. Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron. 2016;91:1199–218.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Nicola J. Ray has received research funding through a grant from The Wellcome Trust. Martijn L.T.M. Müller has received research funding through grants from the National Institutes of Health (NIH) and the Department of Veterans Affairs. Nicolaas I. Bohnen has received research funding through grants from the NIH, the Department of Veterans Affairs, the Michael J. Fox Foundation, Eisai, EIP Pharma, and Axovant Gene Therapies; has received compensation from Eisai for participating on an advisory board; and has received in-kind research support from Expansion Therapeutics and Innovative Health Solutions.

Author information

Authors and Affiliations

  1. Department of Psychology, Manchester Metropolitan University, Manchester, UK

    Chesney E. Craig & Nicola J. Ray

  2. Health, Psychology and Communities Research Centre, Manchester Metropolitan University, Manchester, UK

    Chesney E. Craig & Nicola J. Ray

  3. Department of Radiology, University of Michigan, Ann Arbor, MI, 48105, USA

    Martijn L. T. M. Müller & Nicolaas I. Bohnen

  4. Morris K. Udall Center of Excellence for Parkinson’s Disease Research, University of Michigan, Ann Arbor, MI, 48105, USA

    Martijn L. T. M. Müller & Nicolaas I. Bohnen

  5. Veterans Administration Ann Arbor Healthcare System, Ann Arbor, MI, 48105, USA

    Nicolaas I. Bohnen

Authors
  1. Chesney E. Craig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola J. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martijn L. T. M. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicolaas I. Bohnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolaas I. Bohnen.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Geropsychiatry & Cognitive Disorders of Late Life

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Craig, C.E., Ray, N.J., Müller, M.L.T.M. et al. New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders. Curr Behav Neurosci Rep 7, 278–286 (2020). https://doi.org/10.1007/s40473-020-00221-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40473-020-00221-6

Keywords

Search

Navigation